Name | Canlitinib |
---|
Description | Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for cancer study. |
---|---|
Related Catalog | |
References |
Molecular Formula | C33H31F2N3O7 |
---|---|
Molecular Weight | 619.61 |